DrugPatentWatch Database Preview

Cipla Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?

CIPLA has ninety-three approved drugs.

There are four US patents protecting CIPLA drugs. There are thirty-one tentative approvals on CIPLA drugs.

There are twenty-three patent family members on CIPLA drugs in twenty-one countries and three hundred and eighty-four supplementary protection certificates in seventeen countries.

Summary for Cipla

International Patents:	23
US Patents:	4
Tradenames:	84
Ingredients:	84
NDAs:	93
Patent Litigation for Cipla:	See patent lawsuits for Cipla
PTAB Cases with Cipla as petitioner:	See PTAB cases with Cipla as petitioner

Drugs and US Patents for Cipla

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	PREGABALIN	pregabalin	CAPSULE;ORAL	212280-006	Jan 10, 2020	AB	RX	No	No
Cipla	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211291-001	May 28, 2019		DISCN	No	No
Cipla	LAMIVUDINE	lamivudine	TABLET;ORAL	077221-002	Mar 3, 2017	AB	RX	No	No
Cipla	CINACALCET HYDROCHLORIDE	cinacalcet hydrochloride	TABLET;ORAL	208915-002	Mar 8, 2018	AB	RX	No	No
Cipla Ltd	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	077518-002	May 31, 2011	AB	RX	No	No
Cipla	GEMCITABINE HYDROCHLORIDE	gemcitabine hydrochloride	INJECTABLE;INJECTION	078759-001	Jul 25, 2011	AP	RX	No	No
Cipla	PREGABALIN	pregabalin	CAPSULE;ORAL	212280-002	Jan 10, 2020	AB	RX	No	No

International Patents for Cipla Drugs

Country	Patent Number	Estimated Expiration
Japan	2011219498
Croatia	P20170154
Slovenia	2217610
Israel	205880
Lithuania	2217610
Brazil	PI0819319
China	103360440

Supplementary Protection Certificates for Cipla Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0122707	96C0030	Belgium		PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327
1131065	92488	Luxembourg		PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140130
2203431	CR 2015 00014	Denmark		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0915894	SPC/GB05/041	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB05/041 GRANTED TO GILEAD SCIENCES, INC. IN RESPECT OF THE PRODUCT COMPOSITION CONTAINING BOTH TENOFOVIR DISOPROXIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, TAUTOMER OR SOLVATE THEREOF, TOGETHER WITH EMTRICITABINE , THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6233 DATED 05/11/2008 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 23/02/2020.
1912999	2014/058	Ireland		PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
1663240	223 5021-2015	Slovakia		PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
1663240	300851	Netherlands		PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cipla
• Cipla Ltd
• Cipla Usa